NCT04729387 2026-03-13
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
Clinical Trials
12 trialsNCT04967248 2025-12-04
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Novartis
Terminated
NCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
NCT04216472 2025-09-30
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT03601507 2024-04-17
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
University of Arizona
Phase 2 Terminated
NCT04801966 2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA Terminated
NCT03386162 2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2 Terminated
NCT02734615 2022-08-01
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Novartis
Phase 1 Terminated
NCT02550743 2021-03-12
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
Brown University
Phase 1 Terminated
NCT01708161 2018-09-13
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Novartis
Phase 1/2 Terminated